Varruchi Sharma
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Varruchi Sharma has a total of 56 co-authors. Here are the top co-authors by number of shared publications:
- Anil Kumar Sharma
Department of Biotechnology, Sector-82-A, IT City Road, Amity University, Mohali-140306 Punjab
15 shared publications - Kuldeep Dhama
Division of Pathology, ICAR-Indian Veterinary Research Institute, Bareilly, India
8 shared publications - Abhijit Dey
Department of Life Sciences, Presidency University, Kolkata, India
5 shared publications - Ajay Sharma
Department of Chemistry Career Point University Hamirpur Himachal Pradesh India
4 shared publications - Anil Panwar
Department of Bioinformatics and Computational Biology CCS Haryana Agricultural University Hisar India
4 shared publications - Deepak Chandran
Department of Veterinary Sciences and Animal Husbandry, Amrita School of Agricultural Sciences, Amrita Vishwa Vidyapeetham University, Coimbatore 642109, India
4 shared publications
Latest Publications
- Open Access
- 19 May 2026
- Published by Open Exploration Publishing in Exploration of Foods and Foodomics
- Vol. 4, 1010149
Edible insect nutrition and bioinformatics based nutritional assessment
Edible insects are a sustainable food source, due to their high nutritional value and low environmental impact. This review explores how bioinformatics improves the nutritional value and farming efficiency of edible insects, focusing on Tenebrio molitor (mealworms), Hermetia illucens [black soldier fly larvae (BSFL)], and Acheta domesticus (crickets). These insects provide micronutrients like vitamin B12 and iron with 10% to 50% lipids and 30% to 70% protein. Bioinformatics is enhancing the breeding and sustainability of insects, which optimizes nutrient extraction through genomic and metabolomic analyses done by using tools like NCBI and KEGG. For commercial farming, A. domesticus and T. molitor are ideal, while BSFL are excellent in waste recycling. Unlike previous reviews centered primarily on compositional analysis, this review uniquely links genomic and metabolomic bioinformatics approaches with targeted nutritional optimization in edible insect production. Despite these advantages, challenges such as regulatory gaps, high computational costs, consumer demand in Western markets, and acceptance of insect produced products by consumers are still the challenges for their scalability. Insect farming by using bioinformatics reduces environmental impacts and offers a scalable, sustainable solution to global food security. Continued research into cost-effective computational methods and consumer acceptance strategies is essential to introduce insects into food systems. All the data present in review are broadly representative of edible insects, values fall within these intervals but vary according to feed substrate and production system.
- 19 May 2026
- Published by Open Exploration Publishing in Exploration of Foods and Foodomics
- Vol. 4, 1010149
Open AccessEdible insect nutrition and bioinformatics based nutritional assessment
Edible insects are a sustainable food source, due to their high nutritional value and low environmental impact. This review explores how bioinformatics improves the nutritional value and farming efficiency of edible insects, focusing on Tenebrio molitor (mealworms), Hermetia illucens [black soldier fly larvae (BSFL)], and Acheta domesticus (crickets). These insects provide micronutrients like vitamin B12 and iron with 10% to 50% lipids and 30% to 70% protein. Bioinformatics is enhancing the breeding and sustainability of insects, which optimizes nutrient extraction through genomic and metabolomic analyses done by using tools like NCBI and KEGG. For commercial farming, A. domesticus and T. molitor are ideal, while BSFL are excellent in waste recycling. Unlike previous reviews centered primarily on compositional analysis, this review uniquely links genomic and metabolomic bioinformatics approaches with targeted nutritional optimization in edible insect production. Despite these advantages, challenges such as regulatory gaps, high computational costs, consumer demand in Western markets, and acceptance of insect produced products by consumers are still the challenges for their scalability. Insect farming by using bioinformatics reduces environmental impacts and offers a scalable, sustainable solution to global food security. Continued research into cost-effective computational methods and consumer acceptance strategies is essential to introduce insects into food systems. All the data present in review are broadly representative of edible insects, values fall within these intervals but vary according to feed substrate and production system.
- Open Access
- 27 June 2025
- Published by Oriental Scientific Publishing Company in Biosciences Biotechnology Research Asia
- Vol. 22 (2) , 535-541
Unveiling the Bacterial Quality and Prevalence of Foodborne Bacteria in Raw Meat Sold at Different Markets in Chandigarh City, India
Raw meat (Chicken) contains various nutrients such as protein, essential fatty acids, minerals, vitamins, and high water content, making it a potential source of foodborne bacterial pathogens. This study aimed to evaluate the bacteriological quality of raw meats from open markets in Chandigarh, India. Fifty meat samples were collected from local markets in Chandigarh and stored at 4 °C. To assess bacteriological quality, a 10-fold serial dilution of the homogenate was performed, and the total viable count (TVC) and total coliform count (TCC) were determined using plate count agar. Morphological, biochemical, and molecular characterization techniques were used to identify bacterial isolates. The mean values of total aerobic count (TAC) in raw meat samples ranged between 2.77x10³ CFU/g and 3.19x10⁴ CFU/g, while the mean TCC values ranged between 3.54x10² CFU/g and 5.73x10² CFU/g. The study found a high prevalence of Escherichia coli (~80%), followed by Staphylococcus aureus (~58%), Salmonella spp. (~35%), Bacillus subtilis (~30%), Micrococcus luteus (~20%), and Pseudomonas aeruginosa (~10%) in raw meat. The findings of this study highlight that raw meat samples from open markets carry a substantial microbial load, with the presence of various bacterial strains indicating potential contamination. This contamination poses a significant risk of foodborne illnesses, especially when meat is consumed raw or improperly cooked.
- 27 June 2025
- Published by Oriental Scientific Publishing Company in Biosciences Biotechnology Research Asia
- Vol. 22 (2) , 535-541
Open AccessUnveiling the Bacterial Quality and Prevalence of Foodborne Bacteria in Raw Meat Sold at Different Markets in Chandigarh City, India
Raw meat (Chicken) contains various nutrients such as protein, essential fatty acids, minerals, vitamins, and high water content, making it a potential source of foodborne bacterial pathogens. This study aimed to evaluate the bacteriological quality of raw meats from open markets in Chandigarh, India. Fifty meat samples were collected from local markets in Chandigarh and stored at 4 °C. To assess bacteriological quality, a 10-fold serial dilution of the homogenate was performed, and the total viable count (TVC) and total coliform count (TCC) were determined using plate count agar. Morphological, biochemical, and molecular characterization techniques were used to identify bacterial isolates. The mean values of total aerobic count (TAC) in raw meat samples ranged between 2.77x10³ CFU/g and 3.19x10⁴ CFU/g, while the mean TCC values ranged between 3.54x10² CFU/g and 5.73x10² CFU/g. The study found a high prevalence of Escherichia coli (~80%), followed by Staphylococcus aureus (~58%), Salmonella spp. (~35%), Bacillus subtilis (~30%), Micrococcus luteus (~20%), and Pseudomonas aeruginosa (~10%) in raw meat. The findings of this study highlight that raw meat samples from open markets carry a substantial microbial load, with the presence of various bacterial strains indicating potential contamination. This contamination poses a significant risk of foodborne illnesses, especially when meat is consumed raw or improperly cooked.
- 17 January 2024
- Published by Springer Nature in Food Science and Biotechnology
- Vol. 33 (9) , 2035-2045
Dietary mung bean as promising food for human health: gut microbiota modulation and insight into factors, regulation, mechanisms and therapeutics—an update
Plant-based functional foods have gained wider attention in current scenario with mung bean harboring several bioactive compounds with promising gut health benefits and pharmacological importance. Consumption of mung bean has a positive impact on beneficial gut microbes and microbial metabolite production. The effects of dietary mung bean on gut microbial homeostasis and the management of gut-related diseases along with the possible mechanism of action, have been highlighted through this review paving a way for a promising role of dietary mung bean as a functional food in the management of gut-related diseases for example mung bean peptides can help not only in treating prediabetes but also delaying the aging process by targeting the intestinal microflora. In addition, expanding our knowledge of how diets affect host health and disease, including the effects of mung bean dietary components on gut microbiota-derived metabolites, will eventually allow for the development of tailored diets and nutrients.
- 17 January 2024
- Published by Springer Nature in Food Science and Biotechnology
- Vol. 33 (9) , 2035-2045
Dietary mung bean as promising food for human health: gut microbiota modulation and insight into factors, regulation, mechanisms and therapeutics—an update
Plant-based functional foods have gained wider attention in current scenario with mung bean harboring several bioactive compounds with promising gut health benefits and pharmacological importance. Consumption of mung bean has a positive impact on beneficial gut microbes and microbial metabolite production. The effects of dietary mung bean on gut microbial homeostasis and the management of gut-related diseases along with the possible mechanism of action, have been highlighted through this review paving a way for a promising role of dietary mung bean as a functional food in the management of gut-related diseases for example mung bean peptides can help not only in treating prediabetes but also delaying the aging process by targeting the intestinal microflora. In addition, expanding our knowledge of how diets affect host health and disease, including the effects of mung bean dietary components on gut microbiota-derived metabolites, will eventually allow for the development of tailored diets and nutrients.
- 5 January 2024
- Published by Elsevier in Colloids and Surfaces B: Biointerfaces
- Vol. 234, 113745
Current paradigms in employing self-assembled structures: Drug delivery implications with improved therapeutic potential
- 5 January 2024
- Published by Elsevier in Colloids and Surfaces B: Biointerfaces
- Vol. 234, 113745
Current paradigms in employing self-assembled structures: Drug delivery implications with improved therapeutic potential
- Open Access
- 1 March 2023
- Published by Journal of Pure and Applied Microbiology in Journal of Pure and Applied Microbiology
- Vol. 17 (1) , 385-394
Computational Docking Study of the Phytochemical Constituent, Silybin (Silybum marianum) against SARS-CoV-2 Omicron Variant Spike Glycoprotein: An In-silico Approach
SARS-CoV-2 is continually evolving with the emergence of new variants with increased viral pathogenicity. The emergence of heavily mutated Omicron (B.1.1.529) with spike protein mutations are known to mediate its higher transmissibility and immune escape that has brought newer challenges for global public health to contain SARS-CoV-2 infection. One has to come up with a therapeutic strategy against the virus so as to effectively contain the infection and spread. Natural phytochemicals are being considered a significant source of bioactive compounds possessing an antiviral therapeutic potential. Being a promising anticancer and chemo-preventive agent, Silybin holds a significant potential to be used as a therapeutic. In the present study, molecular docking of Silybin with Omicron spike protein (7QNW) was carried out. Molecular docking results showed greater stability of Silybin in the active site of the Omicron spike protein with suitable binding mode of interactions. The study reveals that Silybin has the potential to block the host ACE2 receptor-viral spike protein binding; thereby inhibiting the viral entry to human cells. Therefore, Silybin may be further developed as a medication with the ability to effectively combat SARS-CoV-2 Omicron.
- 1 March 2023
- Published by Journal of Pure and Applied Microbiology in Journal of Pure and Applied Microbiology
- Vol. 17 (1) , 385-394
Open AccessComputational Docking Study of the Phytochemical Constituent, Silybin (Silybum marianum) against SARS-CoV-2 Omicron Variant Spike Glycoprotein: An In-silico Approach
SARS-CoV-2 is continually evolving with the emergence of new variants with increased viral pathogenicity. The emergence of heavily mutated Omicron (B.1.1.529) with spike protein mutations are known to mediate its higher transmissibility and immune escape that has brought newer challenges for global public health to contain SARS-CoV-2 infection. One has to come up with a therapeutic strategy against the virus so as to effectively contain the infection and spread. Natural phytochemicals are being considered a significant source of bioactive compounds possessing an antiviral therapeutic potential. Being a promising anticancer and chemo-preventive agent, Silybin holds a significant potential to be used as a therapeutic. In the present study, molecular docking of Silybin with Omicron spike protein (7QNW) was carried out. Molecular docking results showed greater stability of Silybin in the active site of the Omicron spike protein with suitable binding mode of interactions. The study reveals that Silybin has the potential to block the host ACE2 receptor-viral spike protein binding; thereby inhibiting the viral entry to human cells. Therefore, Silybin may be further developed as a medication with the ability to effectively combat SARS-CoV-2 Omicron.
- Open Access
- 1 March 2023
- Published by Wolters Kluwer Health in International Journal of Surgery
- Vol. 109 (3) , 564-567
Dietary patterns and fertility status in men: Mediterranean diet does make a difference in ameliorating the rise in male infertility problems due to changing lifestyle
An abstract is unavailable. This article is available as a PDF only.
- 1 March 2023
- Published by Wolters Kluwer Health in International Journal of Surgery
- Vol. 109 (3) , 564-567
Open AccessDietary patterns and fertility status in men: Mediterranean diet does make a difference in ameliorating the rise in male infertility problems due to changing lifestyle
An abstract is unavailable. This article is available as a PDF only.
- Open Access
- 30 December 2022
- Published by Journal of Pure and Applied Microbiology in Journal of Pure and Applied Microbiology
- Vol. 16 (suppl 1) , 3000-3012
An overview on Monkeypox, Current Paradigms and Advances in its Vaccination, Treatment and Clinical Management: Trends, Scope, Promise and Challenges
Monkeypox virus is an orthopoxvirus sharing the common genus with variola and vaccinia virus. Most of the monkeypox (MPX) cases had been reported from the central and west African region (the main endemic areas) prior to 2022 but there was a sudden outbreak in May, 2022 disseminating the infections to thousands of people even in non-endemic countries, posing a global public health emergency. MPX was considered a rae and neglected disease, however the 2022 MPX outbreaks in multiple countries attracted attention of worldwide researchers to pace up for carrying out researches on various aspects of MPXV including attempts to design and develop diagnostics, vaccines, drugs and therapeutics counteract MPX. Apart from being a zoonotic disease, the current outbreaks highlighted rapid human-to-human transmission of MPXV, besides the reverse zoonosis has also been documented with recent first report of human-to-dog transmission, urging a call for the importance of one health approach. Atypical and unusual disease manifestations as well asymptomatic MPXV infections have also been observed during 2022 MPX outbreak. The affected patients typically develop a rash resulting in a mild disease followed by recovery with some supportive care and use of antivirals such as tecovirimat, cidofovir and brincidofovir in severe disease cases. Modified vaccinia Ankara (MVA) vaccine with an excellent safety profile has been recommended to patients with higher risk exposure and immunocompromised individuals. Moreover, another vaccine the replication-competent vaccine (ACAM2000) could be a suitable alternative to MVA’s non-availability to some selective immunocompetent individuals. Current review highlights the salient aspects of management and treatment of monkeypox along with underlying promises in terms of therapeutics and a variety of challenges posed due to current global public health emergency situation to counteract MPX.
- 30 December 2022
- Published by Journal of Pure and Applied Microbiology in Journal of Pure and Applied Microbiology
- Vol. 16 (suppl 1) , 3000-3012
Open AccessAn overview on Monkeypox, Current Paradigms and Advances in its Vaccination, Treatment and Clinical Management: Trends, Scope, Promise and Challenges
Monkeypox virus is an orthopoxvirus sharing the common genus with variola and vaccinia virus. Most of the monkeypox (MPX) cases had been reported from the central and west African region (the main endemic areas) prior to 2022 but there was a sudden outbreak in May, 2022 disseminating the infections to thousands of people even in non-endemic countries, posing a global public health emergency. MPX was considered a rae and neglected disease, however the 2022 MPX outbreaks in multiple countries attracted attention of worldwide researchers to pace up for carrying out researches on various aspects of MPXV including attempts to design and develop diagnostics, vaccines, drugs and therapeutics counteract MPX. Apart from being a zoonotic disease, the current outbreaks highlighted rapid human-to-human transmission of MPXV, besides the reverse zoonosis has also been documented with recent first report of human-to-dog transmission, urging a call for the importance of one health approach. Atypical and unusual disease manifestations as well asymptomatic MPXV infections have also been observed during 2022 MPX outbreak. The affected patients typically develop a rash resulting in a mild disease followed by recovery with some supportive care and use of antivirals such as tecovirimat, cidofovir and brincidofovir in severe disease cases. Modified vaccinia Ankara (MVA) vaccine with an excellent safety profile has been recommended to patients with higher risk exposure and immunocompromised individuals. Moreover, another vaccine the replication-competent vaccine (ACAM2000) could be a suitable alternative to MVA’s non-availability to some selective immunocompetent individuals. Current review highlights the salient aspects of management and treatment of monkeypox along with underlying promises in terms of therapeutics and a variety of challenges posed due to current global public health emergency situation to counteract MPX.
- Open Access
- 30 December 2022
- Published by Journal of Pure and Applied Microbiology in Journal of Pure and Applied Microbiology
- Vol. 16 (suppl 1) , 3168-3178
Tecovirimat as a Potential Bioavailable inhibitor against MPXVgp158 Established through Molecular Dynamic Simulations and Docking Studies
Monkeypox is a zoonotic viral infection caused by monkeypox virus which belongs to the Poxviridae family of genus Orthopoxvirus. Usually, the virus transmission happens when the individual comes in contact with the infected person through body fluids, animal lesions, respiratory droplets or through virus contaminated materials. Clinical presentation of the monkeypox has shown significant resemblance to that of smallpox and chickenpox, belonging to the same orthopoxvirus genus but were eradicated during 1980s globally. Monkeypox may lead to a range of medical complications including clinical symptoms like fever, rashes, headaches, back pain, myodynia and swollen lymph nodes. As far as the treatment modalities are concerned, the antiviral therapeutic agents developed for the smallpox treatment, were also permitted to be used for the monkeypox treatment. However, there is no proven treatment for human monkeypox. In the current study, we have focused on designing of a best probable ligand against the target MPXVgp158 (Monkeypox virus protein). Since Tecovirimat is an FDA approved compound known as an antipoxviral drug, the study aimed to develop a Monkeypox virus protein MPXVgp158 inhibitor which is bioavailable and biocompatible as well through drug designing using computational tools. Molecular docking (MD) analysis displayed Tecovirimat with lesser binding energy, higher non-bonded interaction capability, and more stability against MPXVgp158, with efficient binding mode of interactions. Hence, Tecovirimat was adjudged to be the potential candidate against MPXVgp158 inhibition.
- 30 December 2022
- Published by Journal of Pure and Applied Microbiology in Journal of Pure and Applied Microbiology
- Vol. 16 (suppl 1) , 3168-3178
Open AccessTecovirimat as a Potential Bioavailable inhibitor against MPXVgp158 Established through Molecular Dynamic Simulations and Docking Studies
Monkeypox is a zoonotic viral infection caused by monkeypox virus which belongs to the Poxviridae family of genus Orthopoxvirus. Usually, the virus transmission happens when the individual comes in contact with the infected person through body fluids, animal lesions, respiratory droplets or through virus contaminated materials. Clinical presentation of the monkeypox has shown significant resemblance to that of smallpox and chickenpox, belonging to the same orthopoxvirus genus but were eradicated during 1980s globally. Monkeypox may lead to a range of medical complications including clinical symptoms like fever, rashes, headaches, back pain, myodynia and swollen lymph nodes. As far as the treatment modalities are concerned, the antiviral therapeutic agents developed for the smallpox treatment, were also permitted to be used for the monkeypox treatment. However, there is no proven treatment for human monkeypox. In the current study, we have focused on designing of a best probable ligand against the target MPXVgp158 (Monkeypox virus protein). Since Tecovirimat is an FDA approved compound known as an antipoxviral drug, the study aimed to develop a Monkeypox virus protein MPXVgp158 inhibitor which is bioavailable and biocompatible as well through drug designing using computational tools. Molecular docking (MD) analysis displayed Tecovirimat with lesser binding energy, higher non-bonded interaction capability, and more stability against MPXVgp158, with efficient binding mode of interactions. Hence, Tecovirimat was adjudged to be the potential candidate against MPXVgp158 inhibition.
- Open Access
- 31 October 2022
- Published by Journal of Experimental Biology and Agricultural Sciences in Journal of Experimental Biology and Agricultural Sciences
- Vol. 10 (5) , 1016-1023
In-silico designing of an inhibitor against mTOR FRB domain: Therapeutic implications against breast cancer
Worldwide breast cancer causes significant fatalities in women. The effective therapeutic solution for treating the disease is using new and probable antagonistic biologically available ligands as anticancer drugs. To identify a successful therapeutic approach, the scientific community is now interested in creating novel ligands that in the future may be used as anticancer drugs. The mechanistic target of rapamycin (mTOR) is a protein kinase connected to several processes governing immunity, metabolism, cell development, and survival. The proliferation and metastasis of tumors have both been linked to the activation of the mTOR pathway. Female breast cancer represents about 15.3% of all new cancer cases in the U.S. alone and is frequently diagnosed among women aged 55 to 69 years. Given that the P13K/AKT/mTOR pathway is one of the most often activated in cancer, much attention has been paid to its resistance as a novel oncological treatment approach. mTOR/FRB Domain’s recruitment cleft as, well as substrate recruitment mechanism, was targeted using a structural-based approach. A series of selective inhibitory small molecules have been designed and screened for the best inhibiting target binding triad of the FRB Domain with better ADME and no detectable toxic effects.
- 31 October 2022
- Published by Journal of Experimental Biology and Agricultural Sciences in Journal of Experimental Biology and Agricultural Sciences
- Vol. 10 (5) , 1016-1023
Open AccessIn-silico designing of an inhibitor against mTOR FRB domain: Therapeutic implications against breast cancer
Worldwide breast cancer causes significant fatalities in women. The effective therapeutic solution for treating the disease is using new and probable antagonistic biologically available ligands as anticancer drugs. To identify a successful therapeutic approach, the scientific community is now interested in creating novel ligands that in the future may be used as anticancer drugs. The mechanistic target of rapamycin (mTOR) is a protein kinase connected to several processes governing immunity, metabolism, cell development, and survival. The proliferation and metastasis of tumors have both been linked to the activation of the mTOR pathway. Female breast cancer represents about 15.3% of all new cancer cases in the U.S. alone and is frequently diagnosed among women aged 55 to 69 years. Given that the P13K/AKT/mTOR pathway is one of the most often activated in cancer, much attention has been paid to its resistance as a novel oncological treatment approach. mTOR/FRB Domain’s recruitment cleft as, well as substrate recruitment mechanism, was targeted using a structural-based approach. A series of selective inhibitory small molecules have been designed and screened for the best inhibiting target binding triad of the FRB Domain with better ADME and no detectable toxic effects.
- Open Access
- 30 August 2022
- Published by Journal of Experimental Biology and Agricultural Sciences in Journal of Experimental Biology and Agricultural Sciences
- Vol. 10 (4) , 840-845
In-silico designing of a potent ligand molecule against PTEN (Phosphatase and tensin homolog) implicated in Breast Cancer
Breast cancer has been attributed to be the second most common malignancy in females worldwide after skin cancer associated with a significantly high mortality rate. Tumor suppressor genes have an indispensable role in maintaining genomic integrity as well as cell cycle regulation. Phosphatase and tensin homolog deleted on chromosome ten (PTEN) is one of the most frequently mutated human tumor suppressor genes, implicated in cell growth, survival, and suppressing tumor formation. As the tumor progresses to more advanced stages, genetic alterations tend to increase one such alteration is the mutation of the PTEN gene which is linked to programmed cell death and maintenance of cell cycle regulation. There is a syndrome known as Cowden syndrome associated with a high risk of breast cancer which is a result of an outcome of germline mutations in the PTEN gene. Loss of PTEN activity, either at the protein or genomic level, has been related to many primary and metastatic malignancies including breast cancer. This study focuses on developing a potential bioavailable ligand inhibitory molecule for PTEN, using a computer-aided drug design approach (CADD). A library of developed ligands consisting of 50 potential molecules was screened to find a potential candidate to be used for second generation drug development. Among them, LIG28 was adjudged as the most effective and potential PTEN inhibitor given its maximum binding affinity of ΔG -5.96Kcal/mole with a lower RMSD value. Carmer’s Rule of toxicity further revealed the compatibility and non-toxicity of the molecule. These observations underscore the importance of PTEN as a target in the development of tumorigenesis and the prognosis of breast cancer.
- 30 August 2022
- Published by Journal of Experimental Biology and Agricultural Sciences in Journal of Experimental Biology and Agricultural Sciences
- Vol. 10 (4) , 840-845
Open AccessIn-silico designing of a potent ligand molecule against PTEN (Phosphatase and tensin homolog) implicated in Breast Cancer
Breast cancer has been attributed to be the second most common malignancy in females worldwide after skin cancer associated with a significantly high mortality rate. Tumor suppressor genes have an indispensable role in maintaining genomic integrity as well as cell cycle regulation. Phosphatase and tensin homolog deleted on chromosome ten (PTEN) is one of the most frequently mutated human tumor suppressor genes, implicated in cell growth, survival, and suppressing tumor formation. As the tumor progresses to more advanced stages, genetic alterations tend to increase one such alteration is the mutation of the PTEN gene which is linked to programmed cell death and maintenance of cell cycle regulation. There is a syndrome known as Cowden syndrome associated with a high risk of breast cancer which is a result of an outcome of germline mutations in the PTEN gene. Loss of PTEN activity, either at the protein or genomic level, has been related to many primary and metastatic malignancies including breast cancer. This study focuses on developing a potential bioavailable ligand inhibitory molecule for PTEN, using a computer-aided drug design approach (CADD). A library of developed ligands consisting of 50 potential molecules was screened to find a potential candidate to be used for second generation drug development. Among them, LIG28 was adjudged as the most effective and potential PTEN inhibitor given its maximum binding affinity of ΔG -5.96Kcal/mole with a lower RMSD value. Carmer’s Rule of toxicity further revealed the compatibility and non-toxicity of the molecule. These observations underscore the importance of PTEN as a target in the development of tumorigenesis and the prognosis of breast cancer.